Abstract
ATENA (Adjuvant post-Tamoxifen Exemestane versus Nothing Applied): a phase III randomized parallel-group multicenter trial, designed to compare 5 Years of adjuvant exemestane versus 5 years of observation in postmenopausal women with operable breast cancer who have received 5–7 years of adjuvant tamoxifen. The primary endpoint is disease-free survival. The effects of extended adjuvant therapy with exemestane on the lipid profile was a secondary endpoint. This trial was prematurely discontinued in November 2005 due to poor accrual following publication of the results of the MA.17 trial, which demonstrated a reduced risk of recurrence with extended adjuvant therapy using letrozole.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
